Should I buy or sell Omeros stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares. View OMER analyst ratings or view top-rated stocks .

How have OMER shares performed in 2024?

Omeros' stock was trading at $3.27 at the start of the year. Since then, OMER shares have decreased by 6.7% and is now trading at $3.05. View the best growth stocks for 2024 here .

When is Omeros' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our OMER earnings forecast .

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) released its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The biopharmaceutical company had revenue of $30 million for the quarter, compared to the consensus estimate of $29.31 million. During the same period in the previous year, the company earned ($0.39) earnings per share.

What guidance has Omeros issued on next quarter's earnings?

Omeros issued an update on its first quarter 2024 earnings guidance on Monday, April, 1st. The company provided earnings per share (EPS) guidance of -0.630--0.580 for the period. The company issued revenue guidance of -.

What is Gregory A. Demopulos' approval rating as Omeros' CEO?

17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com . Gregory A. Demopulos has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Omeros own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD) , Exelixis (EXEL) , Array Technologies (ARRY) , Inovio Pharmaceuticals (INO) , Ocular Therapeutix (OCUL) , Alibaba Group (BABA) , Sangamo Therapeutics (SGMO) , Verastem (VSTM) , Bausch Health Companies (BHC) and Celldex Therapeutics (CLDX) .

How do I buy shares of Omeros?

Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Omeros have any subsidiaries?

The following companies are subsidiares of Omeros: Nura. Read More

NASDAQ:OMER

Omeros (OMER) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free OMER Stock Alerts

$3.05

-0.16 (-4.98%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.03
▼
$3.25
50-Day Range: $3.05
▼
$4.89
52-Week Range: $0.92
▼
$7.80

Volume: 385,937 shs
Average Volume: 565,899 shs
Market Capitalization: $176.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Omeros alerts:

Omeros MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
23.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.30
Upright™ Environmental Score
News Sentiment: 0.57
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.38 out of 5 stars

Medical Sector

877th out of 911 stocks

Pharmaceutical Preparations Industry

395th out of 411 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Omeros.

1.0

Short Interest

Percentage of Shares Shorted
23.90% of the float of Omeros has been sold short.
Short Interest Ratio / Days to Cover
Omeros has a short interest ratio ("days to cover") of 23.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Omeros has recently decreased by 2.28%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Omeros does not currently pay a dividend.
Dividend Growth
Omeros does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Omeros has received a 67.78% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for mental health" products. See details.
Environmental Sustainability
The Environmental Impact score for Omeros is -1.30.

2.0

News and Social Media Coverage

News Sentiment
Omeros has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Omeros this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for OMER on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
4 people have added Omeros to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Omeros insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.90% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
48.79% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Omeros is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Omeros is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

About Omeros Stock (NASDAQ:OMER)

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

OMER Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OMER Stock News Headlines

April 17, 2024 | msn.com

Omeros (OMER) Price Target Increased by 230.77% to 43.86

April 16, 2024 | americanbankingnews.com

Omeros (NASDAQ:OMER) Share Price Passes Above 200 Day Moving Average of $3.00

April 19, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

April 2, 2024 | marketwatch.com

Omeros Shares Down 6% on Swing to 4Q Loss

April 2, 2024 | finance.yahoo.com

Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript

April 2, 2024 | finance.yahoo.com

Q4 2023 Omeros Corp Earnings Call

April 1, 2024 | investorplace.com

OMER Stock Earnings: Omeros Misses EPS for Q4 2023

April 1, 2024 | finance.yahoo.com

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

April 19, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

April 1, 2024 | finance.yahoo.com

Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results

March 27, 2024 | businesswire.com

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

March 19, 2024 | finance.yahoo.com

OMER Aug 2024 3.000 put

March 3, 2024 | finance.yahoo.com

OMER Aug 2024 5.000 put

March 1, 2024 | gurufocus.com

Omeros Corporation - Special Call Transcript

March 1, 2024 | gurufocus.com

Q3 2020 Omeros Corp Earnings Call Transcript

March 1, 2024 | gurufocus.com

Omeros Corp at JPMorgan Healthcare Conference (Virtual) Transcript

March 1, 2024 | gurufocus.com

Q4 2020 Omeros Corp Earnings Call Transcript

March 1, 2024 | gurufocus.com

Q1 2021 Omeros Corp Earnings Call Transcript

March 1, 2024 | gurufocus.com

Omeros Corp at Bank of America NAPA Healthcare Conference (Virtual) Transcript

March 1, 2024 | gurufocus.com

Q2 2021 Omeros Corp Earnings Call Transcript

March 1, 2024 | gurufocus.com

Omeros Corp Regulatory Update Call Transcript

March 1, 2024 | gurufocus.com

Q3 2021 Omeros Corp Earnings Call Transcript

March 1, 2024 | gurufocus.com

Omeros Corp Omidria Call Transcript

March 1, 2024 | gurufocus.com

Q4 2021 Omeros Corp Earnings Call Transcript

March 1, 2024 | gurufocus.com

Q1 2022 Omeros Corp Earnings Call Transcript

March 1, 2024 | gurufocus.com

Q2 2022 Omeros Corp Earnings Call Transcript

March 1, 2024 | gurufocus.com

Q3 2022 Omeros Corp Earnings Call Transcript

See More Headlines

Receive OMER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:OMER
CUSIP: 68214310
CIK: 1285819
Web: www.omeros.com
Phone: (206) 676-5000
Fax: 206-676-5005
Employees: 196
Year Founded: 1994

Profitability

EPS (Most Recent Fiscal Year): ($1.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-117,810,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -1,916.35%
Return on Assets: -35.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.09
Quick Ratio: 4.09

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.40) per share
Price / Book: -7.63

Miscellaneous

Outstanding Shares: 57,940,000
Free Float: 51,627,000
Market Cap: $176.72 million
Optionable: Optionable
Beta: 1.34

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Gregory A. Demopulos M.D. (Age 65)
Co-Founder, Chairman, CEO & President
Comp: $1.79M
Mr. Michael A. Jacobsen (Age 66)
Chief Accounting Officer, VP of Finance & Treasurer
Comp: $518.6k
Mr. Peter B. Cancelmo J.D. (Age 45)
VP, General Counsel & Corporate Secretary
Comp: $503.24k
Dr. Pamela Pierce Palmer M.D. (Age 61)
Ph.D., Co-Founder
Dr. George A. Gaitanaris M.D. (Age 67)
Ph.D., Chief Scientific Officer & VP of Science
Mr. Peter W. Williams (Age 56)
Vice President of Human Resources
Dr. Catherine A. Melfi Ph.D. (Age 65)
Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems
Ms. Nadia Dac (Age 54)
VP & Chief Commercial Officer
Dr. Andreas Grauer M.D. (Age 63)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OMER Stock Analysis - Frequently Asked Questions

Should I buy or sell Omeros stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares.
View OMER analyst ratings or view top-rated stocks.
How have OMER shares performed in 2024?: Omeros' stock was trading at $3.27 at the start of the year. Since then, OMER shares have decreased by 6.7% and is now trading at $3.05.
View the best growth stocks for 2024 here.
When is Omeros' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our OMER earnings forecast.
How were Omeros' earnings last quarter?: Omeros Co. (NASDAQ:OMER) released its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The biopharmaceutical company had revenue of $30 million for the quarter, compared to the consensus estimate of $29.31 million. During the same period in the previous year, the company earned ($0.39) earnings per share.
What guidance has Omeros issued on next quarter's earnings?: Omeros issued an update on its first quarter 2024 earnings guidance on Monday, April, 1st. The company provided earnings per share (EPS) guidance of -0.630--0.580 for the period. The company issued revenue guidance of -.

What is Gregory A. Demopulos' approval rating as Omeros' CEO?: 17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees.
What other stocks do shareholders of Omeros own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Technologies (ARRY), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Alibaba Group (BABA), Sangamo Therapeutics (SGMO), Verastem (VSTM), Bausch Health Companies (BHC) and Celldex Therapeutics (CLDX).
How do I buy shares of Omeros?: Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Omeros have any subsidiaries?: The following companies are subsidiares of Omeros: Nura.
Read More

This page (NASDAQ:OMER) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Omeros (OMER) Stock Price, News & Analysis

Omeros MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Omeros Stock (NASDAQ:OMER)

OMER Stock Price History

OMER Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

OMER Stock Analysis - Frequently Asked Questions

Overall MarketRank^™